NO931372L - Behandling av autoimmunsykdommer ved oral administrering av autoantigener - Google Patents
Behandling av autoimmunsykdommer ved oral administrering av autoantigenerInfo
- Publication number
- NO931372L NO931372L NO93931372A NO931372A NO931372L NO 931372 L NO931372 L NO 931372L NO 93931372 A NO93931372 A NO 93931372A NO 931372 A NO931372 A NO 931372A NO 931372 L NO931372 L NO 931372L
- Authority
- NO
- Norway
- Prior art keywords
- auto
- oral administration
- treatment
- immune diseases
- antigens
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Liquid Crystal (AREA)
- Liquid Crystal Display Device Control (AREA)
- Control Of Indicators Other Than Cathode Ray Tubes (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59693690A | 1990-10-15 | 1990-10-15 | |
PCT/US1991/007542 WO1992006708A1 (en) | 1990-10-15 | 1991-10-15 | Treatment of autoimmune diseases by oral administration of autoantigens |
Publications (3)
Publication Number | Publication Date |
---|---|
NO931372D0 NO931372D0 (no) | 1993-04-14 |
NO931372L true NO931372L (no) | 1993-05-18 |
NO314878B1 NO314878B1 (no) | 2003-06-10 |
Family
ID=24389347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19931372A NO314878B1 (no) | 1990-10-15 | 1993-04-14 | Fremgangsmåte for fremstilling av et farmasöytisk preparat for behandling av reumatoid artritt og multippel sklerose |
Country Status (13)
Country | Link |
---|---|
US (1) | US6019971A (no) |
EP (1) | EP0553291B1 (no) |
JP (1) | JP2635444B2 (no) |
KR (1) | KR0140841B1 (no) |
AT (1) | ATE319474T1 (no) |
AU (2) | AU9023791A (no) |
CA (1) | CA2092905C (no) |
DE (1) | DE69133516T2 (no) |
ES (1) | ES2258261T3 (no) |
HU (1) | HUT69942A (no) |
IL (1) | IL99754A (no) |
NO (1) | NO314878B1 (no) |
WO (1) | WO1992006708A1 (no) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869054A (en) * | 1987-06-24 | 1999-02-09 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of autoantigens |
US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
US6645504B1 (en) | 1987-06-24 | 2003-11-11 | Autoimmune Inc. | Bystander suppression of type I diabetes by oral administration of glucagon |
US5843445A (en) * | 1987-06-24 | 1998-12-01 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
ATE319474T1 (de) * | 1990-10-15 | 2006-03-15 | Autoimmune Inc | Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen |
DK0590060T3 (da) | 1991-06-21 | 1998-05-11 | Univ Cincinnati | Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling |
US6613332B1 (en) | 1991-06-21 | 2003-09-02 | The University Of Cincinnati | Oral administration of therapeutic proteins |
DE4125400C2 (de) * | 1991-07-31 | 2000-08-17 | Edwin Klaus | Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen |
WO1993016724A1 (en) * | 1992-02-28 | 1993-09-02 | Autoimmune, Inc. | Bystander suppression of autoimmune diseases |
JP3845447B2 (ja) * | 1992-09-25 | 2006-11-15 | オートイミューン インク | タイプ▲ii▼コラーゲンによるリウマチ性関節炎治療方法 |
ES2095001T5 (es) * | 1992-12-22 | 2001-03-16 | Univ Cincinnati | Una composicion terapeutica administrable oralmente y su metodo de obtencion. |
EP0609471B1 (de) * | 1993-02-02 | 2000-01-05 | Edwin Dr. Klaus | Verwendung von Kollagen zur Behandlung von krankhaften Gelenkprozessen |
AU674584B2 (en) * | 1993-06-02 | 1997-01-02 | Tvw Telethon Institute For Child Health Research | Cryptic peptides for use in inducing immunologic tolerance |
GB9319429D0 (en) | 1993-09-21 | 1993-11-03 | London Health Ass | Methods and products for controlling immune responses in mammals |
US6251396B1 (en) | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US5856446A (en) * | 1995-07-07 | 1999-01-05 | Autoimmune Inc. | Method of treating rheumatoid arthritis with low dose type II collagen |
ES2320939T3 (es) * | 1996-01-05 | 2009-05-29 | Autoimmune, Inc. | Metodo para la preparacion de colageno de tipo ii. |
AU3225097A (en) * | 1996-06-03 | 1998-01-05 | Auragen, Inc. | Immunotherapy for autoimmune disease |
CA2263730A1 (en) * | 1996-08-15 | 1998-02-19 | Agrivax Incorporated | Delivery of tolerogenic antigens via edible plants or plant-derived products |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US7691829B2 (en) * | 1998-03-24 | 2010-04-06 | Petito George D | Composition and method for healing tissues |
US20050208114A1 (en) * | 1998-03-24 | 2005-09-22 | Petito George D | Composition and method for healing tissues |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US7462486B2 (en) * | 2000-05-12 | 2008-12-09 | Oregon Health & Science University | Methods of selecting T cell receptor V peptides for therapeutic use |
US7371385B2 (en) * | 2000-05-12 | 2008-05-13 | Oregon Health & Science University | Method of treating immune pathologies with low dose estrogen |
ATE367823T1 (de) | 2000-05-24 | 2007-08-15 | Us Health | E-selectin zur behandlung oder vorbeugung von schlaganfall |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
US8053197B2 (en) * | 2004-07-30 | 2011-11-08 | Oregon Health & Science University | Methods for detecting and treating autoimmune disorders |
AR052051A1 (es) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
JP5889529B2 (ja) | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | アミロイド原性疾患の処置 |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
CN104922199A (zh) * | 2015-07-14 | 2015-09-23 | 无限极(中国)有限公司 | 一种保护骨关节组合物及其应用 |
EP3621985A4 (en) | 2017-05-11 | 2021-03-17 | Avicenna Nutraceutical, LLC | METHOD FOR GENERATING COLLAGEN |
WO2021055448A1 (en) * | 2019-09-16 | 2021-03-25 | Figene, Llc | Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4350682A (en) * | 1979-05-11 | 1982-09-21 | Lescarden Ltd. | Cartilage extraction processes and products |
ATE128627T1 (de) * | 1986-06-30 | 1995-10-15 | Massachusetts Inst Technology | Immunomodulare mittel und deren verwendung. |
CA1302880C (en) * | 1986-07-25 | 1992-06-09 | Peter Koepff | Agents for the treatment of arthroses |
US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
US5399347A (en) * | 1987-06-24 | 1995-03-21 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
US5843445A (en) * | 1987-06-24 | 1998-12-01 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
CA1336954C (en) * | 1987-06-24 | 1995-09-12 | Howard L. Weiner | Treatment of autoimmune diseases by oral administration of autoantigens |
CA1340012C (en) * | 1987-08-17 | 1998-08-25 | Trustees Of Leland Stanford Jr. University | Peptide determinant associated with immunity |
DE69033487T2 (de) * | 1989-12-20 | 2000-06-29 | Autoimmune, Inc. | Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol |
US5075112A (en) * | 1990-02-12 | 1991-12-24 | Cartilage Technologies Inc. | Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage |
WO1991012816A1 (en) * | 1990-03-02 | 1991-09-05 | Autoimmune, Inc. | Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens |
ATE319474T1 (de) * | 1990-10-15 | 2006-03-15 | Autoimmune Inc | Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen |
DE4125400C2 (de) * | 1991-07-31 | 2000-08-17 | Edwin Klaus | Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen |
-
1991
- 1991-10-15 AT AT92900084T patent/ATE319474T1/de not_active IP Right Cessation
- 1991-10-15 EP EP92900084A patent/EP0553291B1/en not_active Expired - Lifetime
- 1991-10-15 DE DE69133516T patent/DE69133516T2/de not_active Expired - Lifetime
- 1991-10-15 ES ES92900084T patent/ES2258261T3/es not_active Expired - Lifetime
- 1991-10-15 AU AU90237/91A patent/AU9023791A/en not_active Abandoned
- 1991-10-15 IL IL9975491A patent/IL99754A/en not_active IP Right Cessation
- 1991-10-15 HU HU9301089A patent/HUT69942A/hu unknown
- 1991-10-15 CA CA002092905A patent/CA2092905C/en not_active Expired - Lifetime
- 1991-10-15 WO PCT/US1991/007542 patent/WO1992006708A1/en active IP Right Grant
- 1991-10-15 JP JP4500704A patent/JP2635444B2/ja not_active Expired - Lifetime
- 1991-10-15 KR KR1019930701083A patent/KR0140841B1/ko not_active IP Right Cessation
-
1993
- 1993-04-14 NO NO19931372A patent/NO314878B1/no not_active IP Right Cessation
-
1995
- 1995-06-05 US US08/463,946 patent/US6019971A/en not_active Expired - Lifetime
- 1995-09-01 AU AU30409/95A patent/AU693232B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
ATE319474T1 (de) | 2006-03-15 |
ES2258261T3 (es) | 2006-08-16 |
DE69133516T2 (de) | 2006-08-10 |
HU9301089D0 (en) | 1993-07-28 |
CA2092905A1 (en) | 1992-04-16 |
JP2635444B2 (ja) | 1997-07-30 |
AU693232B2 (en) | 1998-06-25 |
EP0553291B1 (en) | 2006-03-08 |
DE69133516D1 (de) | 2006-05-04 |
US6019971A (en) | 2000-02-01 |
JPH05508662A (ja) | 1993-12-02 |
KR0140841B1 (ko) | 1998-06-01 |
WO1992006708A1 (en) | 1992-04-30 |
AU9023791A (en) | 1992-05-20 |
IL99754A0 (en) | 1992-08-18 |
NO931372D0 (no) | 1993-04-14 |
IL99754A (en) | 1996-08-04 |
AU3040995A (en) | 1995-11-30 |
NO314878B1 (no) | 2003-06-10 |
EP0553291A4 (en) | 1994-11-30 |
KR930702026A (ko) | 1993-09-08 |
EP0553291A1 (en) | 1993-08-04 |
HUT69942A (en) | 1995-09-28 |
CA2092905C (en) | 2002-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO931372L (no) | Behandling av autoimmunsykdommer ved oral administrering av autoantigener | |
ES2190784T3 (es) | Supresion de enfermedades autoinmunes por antigenos espectadores. | |
DK651689D0 (da) | Oralt autoantigenholdigt praeparat | |
GR3033634T3 (en) | Improved treatment of autoimmune diseases by aerosol administration of auto antigens. | |
EA200401473A1 (ru) | Предотвращение и лечение амилоидогенного заболевания | |
NO923395L (no) | Forsterkning av ned-reguleringen av autoimmune sykdommer ved oral administrasjon av autoantigener | |
ZA91559B (en) | Vaccines against cancer and infectious diseases | |
ATE179333T1 (de) | Immunotherapeutische zubereitung | |
SU1739559A1 (ru) | Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |